Video

Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue Sarcoma

Author(s):

Caitlin May, MD

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

In the patient and cell derived xenograft models, olaratumab is seeing the most activity in osteosarcoma and rhabdoid tumor, explains May. When combined with cisplatin, there is an enhancement of activity, but more research must be done.

According to May, oncologists are still trying to better understand the mechanism of action and why olaratumab is advantageous in the preclinical setting. The next step for researchers is going to be looking at different models and the genetic landscape.

Related Videos
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Related Content
FDA
January 10th 2025

GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

FDA
December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
December 29th 2022

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

R. Lor Randall, MD, FACS
December 5th 2024

Preclinical Data Highlight YAP1 and KRAS as Drivers in Soft Tissue Sarcomas

FDA
November 25th 2024

FDA Approves Oral Solution of Imatinib for Certain Leukemias, Other Cancers